FDA Okays First Tardive Dyskinesia Drug

(MedPage Today) -- VMAT2 inhibitor diminished abnormal involuntary movements in pivotal trial
Source: MedPage Today Psychiatry - Category: Psychiatry Source Type: news
More News: Dyskinesia | Psychiatry